Haemonetics Corporation Q3 FY2026 earnings call

• Delivered strong Q3 with $339M revenue, YTD $988M. Adjusted EPS up 10% QoQ and 11% YTD.
• Hospital: BMT growth offset IVT softness. Plasma: Growth from share gains, innovation, and collection volume. Blood center: Driven by international plasma demand.
• Adjusted gross margin 60.2% Q3, 60.5% YTD. Adjusted operating margin 26.3% Q3. Free cash flow $74M Q3, YTD $165M.

Hospital revenue was $144 million in Q3 and $429 million YTD, down 1% QoQ and up 2% YTD organically. Blood Management Technologies saw 8% QoQ and 11% YTD growth, driven by hemostasis management. Interventional Technology revenue declined 12% QoQ and 8% YTD. Plasma revenue was $139 million in Q3, up 3% reported and 20% organic ex CSL QoQ. Blood center revenue was $57 million in Q3, up 3% QoQ and 4% YTD organically.

• Raised full-year revenue, earnings, and free cash flow guidance. Hospital expected ~4% growth. Plasma organic revenue ex CSL 17%-19%. Blood center reported revenue decline 16%-18%, organic growth 1%-3%. Total company reported revenue decline 1%-3%, organic growth 8%-10%. Adjusted EPS FY26 $4.90-$5.

• Factors from SEC filings affecting results. Competitive pressures in interventional technologies. Potential cyclicality in plasma collections.

Q: Rohin Patel asked about plasma growth drivers and FY27 outlook.

A: Chris Simon said plasma growth from share gains, price, and volume; confident in FY27 with positive end-market demand.

Q: Rohin Patel asked about margin step down.

A: James D'Arecca said margin expansion reflects portfolio quality, quarterly unevenness, and smaller increments ahead.

Q: Marie Thibault asked about IVT business.

A: Chris Simon said IVT focus on returning to growth, addressing PFA headwinds, and MVP XL label expansion.

Q: Joanne Wuensch asked about VIVUSHORE acquisition.

A: Chris Simon said VIVUSHORE extends vascular closure leadership, stepwise launch planned.

Q: David Rescott asked about plasma collection growth sustainability.

A: Chris Simon said end-market demand supports sustainability, but volume not directly in guidance.

Q: Anthony Petrone asked about plasma competitor and IVT ASC growth.

A: Chris Simon said strong plasma relationships, IVT ASC growth through corporate account presence.

Q: Mike Matson asked about Savvy Wire.

A: Chris Simon said Savvy Wire had mixed performance, with stabilization expected in FY27.

Q: Michael Petusky asked about hospital guidance.

A: Chris Simon said hospital guidance from BMT strength and IVT stabilization.

Q: Andrew Cooper asked about plasma Q4 and IVT field team.

A: Chris Simon said Q4 prudence, IVT field team with 60% <6 months experience showing improved competitiveness.